Olympics In China Causes Bulk-Drug Prices To Rise In India
This article was originally published in PharmAsia News
Executive Summary
The onset of the Olympics games in China already is having a fallout in India where drug makers are seeing the price of bulk drugs increasing. The Chinese government ordered several chemical firms that make the drugs to cease production temporarily to help reduce air pollution that threatens to plague the sporting events in Beijing. Even though the All India Association of Chemists and Druggists said some prices already have risen in advance of the games, the real impact is yet to be felt. Because of the rise in the price of ranitidine, aminophyline, amoxylitline and ampicillin, some of which have increased by half in the past three months, some Indian drug makers are working hard to find alternate sources. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.